Molecular Mechanisms of Autoimmune Heart Disease

自身免疫性心脏病的分子机制

基本信息

  • 批准号:
    7228543
  • 负责人:
  • 金额:
    $ 46.58万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2004
  • 资助国家:
    美国
  • 起止时间:
    2004-07-15 至 2010-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Autoimmune myocarditis is a major cause of sudden death in children and young adults. Although widely thought to be of infectious etiology, in the majority of cases the cause of disease is unknown. We have discovered that expression of the human HLA class II molecule, HLA-DQ8, in nonobese diabetic mice that lack endogenous murine class II genes results in the spontaneous development of autoimmune myocarditis. Disease was characterized by premature death due to heart failure, destructive lymphocytic infiltrates in the myocardium, and circulating IgG autantibodies against cardiac myosin heavy chain, similar to human myocarditis. Analysis of CD4 T cell clones isolated directly from the heart lesions reveals that, in contrast to the autoantibodies that cross-react with skeletal and cardiac myosin, the CD4 T cells recognize only cardiac myosin, consistent with the cardiac-specificity of this autoimmune disease process. These clones produce large amounts of interferon-gamma, but not IL-4, consistent with a pathogenic Th1 phenotype. The specific aims of this project are: 1) to use the T cell clones a functional probes to identify the epitopes of the myosin 3rotein that are reponsible for the loss of self-tolerance to cardiac myocytes, 2) to identify the primary cellular mediators involved in the pathogenesis of disease and to use congenic strains to determine whether type 1 diabetes and autoimmune myocarditis are controlled by common 'autoimmunity genes', 3) to investigate whether myocarditis in humans is an organ-specific autoimmune disease associated with HLA-DQ8 and whether it can be detected with a combination of HLA typing and immunological testing. These translational studies will involve a collaboration between the PI and Dr. Kenneth Baughman, Director of the Advanced Heart Disease Division at Brigham and Women's Hospital and a leader in the field of myocarditis. The results of these studies could open a new window into the etiology of human myocarditis and lead to improved methods to diagnose and treat this serious disease.
描述(由申请人提供):自身免疫性心肌炎是儿童和年轻人猝死的主要原因。虽然被广泛认为是感染性病因,但在大多数情况下,病因尚不清楚。我们发现,在缺乏内源性小鼠ⅱ类基因的非肥胖糖尿病小鼠中,人类HLAⅱ类分子HLA- dq8的表达会导致自身免疫性心肌炎的自发发展。疾病的特征是由于心力衰竭导致的过早死亡,破坏性的淋巴细胞浸润在心肌中,循环IgG自身抗体对抗心肌肌球蛋白重链,类似于人类心肌炎。对直接从心脏病变中分离的CD4 T细胞克隆的分析表明,与与骨骼和心脏肌球蛋白交叉反应的自身抗体相反,CD4 T细胞只识别心脏肌球蛋白,这与这种自身免疫性疾病过程的心脏特异性一致。这些克隆产生大量的干扰素- γ,但不产生IL-4,这与致病性Th1表型一致。该项目的具体目标是:1)利用T细胞克隆和功能探针鉴定导致心肌细胞自我耐受性丧失的肌球蛋白3蛋白的表位;2)鉴定参与疾病发病机制的主要细胞介质,并利用同源菌株确定1型糖尿病和自身免疫性心肌炎是否由共同的“自身免疫基因”控制。3)探讨人类心肌炎是否是一种与HLA- dq8相关的器官特异性自身免疫性疾病,HLA分型与免疫学检测相结合是否能够检测到。这些转化研究将涉及PI和布里格姆妇女医院高级心脏病科主任,心肌炎领域的领导者Kenneth Baughman博士之间的合作。这些研究结果为了解人类心肌炎的病因打开了一扇新的窗口,并有助于改进这一严重疾病的诊断和治疗方法。

项目成果

期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Myocardial infarction triggers chronic cardiac autoimmunity in type 1 diabetes.
  • DOI:
    10.1126/scitranslmed.3003551
  • 发表时间:
    2012-06-13
  • 期刊:
  • 影响因子:
    17.1
  • 作者:
    Gottumukkala RV;Lv H;Cornivelli L;Wagers AJ;Kwong RY;Bronson R;Stewart GC;Schulze PC;Chutkow W;Wolpert HA;Lee RT;Lipes MA
  • 通讯作者:
    Lipes MA
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MYRA A LIPES其他文献

MYRA A LIPES的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MYRA A LIPES', 18)}}的其他基金

Cardiac Autoimmunity as a Mediator of Cardiovascular Outcomes in Type 1 Diabetes
心脏自身免疫作为 1 型糖尿病心血管结局的调节因素
  • 批准号:
    10427400
  • 财政年份:
    2020
  • 资助金额:
    $ 46.58万
  • 项目类别:
Cardiac Autoimmunity as a Mediator of Cardiovascular Outcomes in Type 1 Diabetes
心脏自身免疫作为 1 型糖尿病心血管结局的调节因素
  • 批准号:
    10252880
  • 财政年份:
    2020
  • 资助金额:
    $ 46.58万
  • 项目类别:
Cardiac Autoimmunity as a Mediator of Cardiovascular Outcomes in Type 1 Diabetes
心脏自身免疫作为 1 型糖尿病心血管结局的调节因素
  • 批准号:
    10034461
  • 财政年份:
    2020
  • 资助金额:
    $ 46.58万
  • 项目类别:
Cardiac Autoantibodies as Biomarkers for Heart Disease in Type 1 Diabetes
心脏自身抗体作为 1 型糖尿病心脏病的生物标志物
  • 批准号:
    9186538
  • 财政年份:
    2015
  • 资助金额:
    $ 46.58万
  • 项目类别:
Autoimmune Mechanisms in the Progression of CVD in Type 1 Diabetes
1 型糖尿病 CVD 进展中的自身免疫机制
  • 批准号:
    7422281
  • 财政年份:
    2005
  • 资助金额:
    $ 46.58万
  • 项目类别:
Autoimmune Mechanisms /Progression of CVD in Type 1 Diab
自身免疫机制/1 型糖尿病的 CVD 进展
  • 批准号:
    6957327
  • 财政年份:
    2005
  • 资助金额:
    $ 46.58万
  • 项目类别:
Autoimmune Mechanisms in the Progression of CVD in T1D
T1D CVD 进展中的自身免疫机制
  • 批准号:
    7095062
  • 财政年份:
    2005
  • 资助金额:
    $ 46.58万
  • 项目类别:
Autoimmune Mechanisms in the Progression of CVD in Type 1 Diabetes
1 型糖尿病 CVD 进展中的自身免疫机制
  • 批准号:
    7233948
  • 财政年份:
    2005
  • 资助金额:
    $ 46.58万
  • 项目类别:
Autoimmune Mechanisms in the Progression of CVD in Type 1 Diabetes
1 型糖尿病 CVD 进展中的自身免疫机制
  • 批准号:
    7619576
  • 财政年份:
    2005
  • 资助金额:
    $ 46.58万
  • 项目类别:
Molecular Mechanisms of Autoimmune Heart Disease
自身免疫性心脏病的分子机制
  • 批准号:
    7074056
  • 财政年份:
    2004
  • 资助金额:
    $ 46.58万
  • 项目类别:

相似海外基金

Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
  • 批准号:
    23K08213
  • 财政年份:
    2023
  • 资助金额:
    $ 46.58万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
  • 批准号:
    2881726
  • 财政年份:
    2023
  • 资助金额:
    $ 46.58万
  • 项目类别:
    Studentship
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
  • 批准号:
    10735090
  • 财政年份:
    2023
  • 资助金额:
    $ 46.58万
  • 项目类别:
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
  • 批准号:
    10722146
  • 财政年份:
    2023
  • 资助金额:
    $ 46.58万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 46.58万
  • 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
  • 批准号:
    10935776
  • 财政年份:
    2023
  • 资助金额:
    $ 46.58万
  • 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
  • 批准号:
    10935796
  • 财政年份:
    2023
  • 资助金额:
    $ 46.58万
  • 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
  • 批准号:
    10935775
  • 财政年份:
    2023
  • 资助金额:
    $ 46.58万
  • 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
  • 批准号:
    10649041
  • 财政年份:
    2023
  • 资助金额:
    $ 46.58万
  • 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
  • 批准号:
    10735964
  • 财政年份:
    2023
  • 资助金额:
    $ 46.58万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了